Convalescent plasma in Covid-19: Possible mechanisms of action

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019(COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study.Meanwhile the current pandemic has called attention over old therapeutic tools to trea...

Full description

Autores:
Rojas, Manuel
Rodríguez, Yhojan
Monsalve, Diana M.
Acosta Ampudia, Yeny
Camacho, Bernardo
Gallo, Juan Esteban
Rojas Villarraga, Adriana
Ramírez Santana, Carolina
Díaz Coronado, Juan C.
Manrique, Rubén
Mantilla, Rubén D.
Shonenfeld, Yehuda
Anaya, Juan Manuel
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Fundación Universitaria de Ciencias de la Salud - FUCS
Repositorio:
Repositorio Digital Institucional ReDi
Idioma:
eng
OAI Identifier:
oai:repositorio.fucsalud.edu.co:001/1719
Acceso en línea:
https://repositorio.fucsalud.edu.co/handle/001/1719
Palabra clave:
Coronavirus
COVID-19
SARS-COV-2
Convalecencia
Citocinas
Inmunoglobinas intravenosas
Anticuerpos neutralizantes
Anticuerpos
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019(COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study.Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases.Convalescent plasma (CP) constitutes thefirst option in the current situation, since it has been successfully usedin other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their re-percussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactiveimmune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of ahypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-criticallyhospitalized patients, in the hope of reducing morbidity and mortality.